Australia's Trans-Pacific Partnership deal to limit intellectual property protections for a new class of drugs called biologics is a major reason the pact has not passed the US Congress, high-profile Republican Senator Orrin Hatch says.
from Top Stories http://ift.tt/29H2Cic